Cargando…
Modulation of the Immune System for the Treatment of Glaucoma
BACKGROUND: At present intraocular pressure (IOP) lowering therapies are the only approach to treat glaucoma. Neuroprotective strategies to protect the retinal ganglion cells (RGC) from apoptosis are lacking to date. Substantial amount of research concerning the role of the immune system in glaucoma...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120111/ https://www.ncbi.nlm.nih.gov/pubmed/28730968 http://dx.doi.org/10.2174/1570159X15666170720094529 |
_version_ | 1783352207962275840 |
---|---|
author | Bell, Katharina von Thun, Nadine Teister, Julia Grus, Franz |
author_facet | Bell, Katharina von Thun, Nadine Teister, Julia Grus, Franz |
author_sort | Bell, Katharina |
collection | PubMed |
description | BACKGROUND: At present intraocular pressure (IOP) lowering therapies are the only approach to treat glaucoma. Neuroprotective strategies to protect the retinal ganglion cells (RGC) from apoptosis are lacking to date. Substantial amount of research concerning the role of the immune system in glaucoma has been performed in the recent years. This review aims to analyse changes found in the peripheral immune system, as well as selected local changes of retina immune cells in the glaucomatous retina. METHODS: By dividing the immune system into the innate and the adaptive immune system, a systematic literature research was performed to find recent approaches concerning the modulation of the immune system in the context of glaucoma. Also ClinicalTrials.gov was assessed to identify studies with a translational context. RESULTS: We found that some aspects of the immune system, such as changes in antibody levels, changes in toll like receptor signalling, T cells and retinal microglial cells, experience more research activity than other areas such as changes in dendritic cells or macrophages. Briefly, results from clinical studies revealed altered immunoreactivities against retinal and optic nerve antigens in sera and aqueous humor of glaucoma patients and point toward an autoimmune involvement in glaucomatous neurodegeneration and RGC death. IgG accumulations along with plasma cells were found localised in human glaucomatous retinae in a pro-inflammatory environment possibly maintained by microglia. Animal studies show that antibodies (e.g. anti- heat shock protein 60 and anti-myelin basic protein) elevated in glaucoma patients provoke autoaggressive RGC loss and are associated with IgG depositions and increased microglial cells. Also, studies addressing changes in T lymphocytes, macrophages but also local immune responses in the retina have been performed and also hold promising results. CONCLUSIONS: This recapitulation of recent literature demonstrates that the immune system definitely plays a role in the pathogenesis of glaucoma. Multiple changes in the peripheral innate as well as adaptive immune system have been detected and give room for further research concerning valuable therapeutic targets. We conclude that there still is a great need to bring together the results derived from basic research analysing different aspects of the immune system in glaucoma to understand the immune context of the disease. Furthermore local immune changes in the retina of glaucoma patients still leave room for further therapeutic targets |
format | Online Article Text |
id | pubmed-6120111 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-61201112019-02-01 Modulation of the Immune System for the Treatment of Glaucoma Bell, Katharina von Thun, Nadine Teister, Julia Grus, Franz Curr Neuropharmacol Article BACKGROUND: At present intraocular pressure (IOP) lowering therapies are the only approach to treat glaucoma. Neuroprotective strategies to protect the retinal ganglion cells (RGC) from apoptosis are lacking to date. Substantial amount of research concerning the role of the immune system in glaucoma has been performed in the recent years. This review aims to analyse changes found in the peripheral immune system, as well as selected local changes of retina immune cells in the glaucomatous retina. METHODS: By dividing the immune system into the innate and the adaptive immune system, a systematic literature research was performed to find recent approaches concerning the modulation of the immune system in the context of glaucoma. Also ClinicalTrials.gov was assessed to identify studies with a translational context. RESULTS: We found that some aspects of the immune system, such as changes in antibody levels, changes in toll like receptor signalling, T cells and retinal microglial cells, experience more research activity than other areas such as changes in dendritic cells or macrophages. Briefly, results from clinical studies revealed altered immunoreactivities against retinal and optic nerve antigens in sera and aqueous humor of glaucoma patients and point toward an autoimmune involvement in glaucomatous neurodegeneration and RGC death. IgG accumulations along with plasma cells were found localised in human glaucomatous retinae in a pro-inflammatory environment possibly maintained by microglia. Animal studies show that antibodies (e.g. anti- heat shock protein 60 and anti-myelin basic protein) elevated in glaucoma patients provoke autoaggressive RGC loss and are associated with IgG depositions and increased microglial cells. Also, studies addressing changes in T lymphocytes, macrophages but also local immune responses in the retina have been performed and also hold promising results. CONCLUSIONS: This recapitulation of recent literature demonstrates that the immune system definitely plays a role in the pathogenesis of glaucoma. Multiple changes in the peripheral innate as well as adaptive immune system have been detected and give room for further research concerning valuable therapeutic targets. We conclude that there still is a great need to bring together the results derived from basic research analysing different aspects of the immune system in glaucoma to understand the immune context of the disease. Furthermore local immune changes in the retina of glaucoma patients still leave room for further therapeutic targets Bentham Science Publishers 2018-08 2018-08 /pmc/articles/PMC6120111/ /pubmed/28730968 http://dx.doi.org/10.2174/1570159X15666170720094529 Text en © 2018 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Bell, Katharina von Thun, Nadine Teister, Julia Grus, Franz Modulation of the Immune System for the Treatment of Glaucoma |
title | Modulation of the Immune System for the Treatment of Glaucoma |
title_full | Modulation of the Immune System for the Treatment of Glaucoma |
title_fullStr | Modulation of the Immune System for the Treatment of Glaucoma |
title_full_unstemmed | Modulation of the Immune System for the Treatment of Glaucoma |
title_short | Modulation of the Immune System for the Treatment of Glaucoma |
title_sort | modulation of the immune system for the treatment of glaucoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120111/ https://www.ncbi.nlm.nih.gov/pubmed/28730968 http://dx.doi.org/10.2174/1570159X15666170720094529 |
work_keys_str_mv | AT bellkatharina modulationoftheimmunesystemforthetreatmentofglaucoma AT vonthunnadine modulationoftheimmunesystemforthetreatmentofglaucoma AT modulationoftheimmunesystemforthetreatmentofglaucoma AT teisterjulia modulationoftheimmunesystemforthetreatmentofglaucoma AT grusfranz modulationoftheimmunesystemforthetreatmentofglaucoma |